Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 11.60%208.68M | 9.76%54.17M | 11.44%53.16M | 11.98%51.15M | 13.41%50.2M | -1.76%187M | 17.59%49.35M | 0.04%47.7M | -9.91%45.67M | -11.45%44.27M |
Operating revenue | 11.60%208.68M | 9.76%54.17M | 11.44%53.16M | 11.98%51.15M | 13.41%50.2M | -1.76%187M | 17.59%49.35M | 0.04%47.7M | -9.91%45.67M | -11.45%44.27M |
Cost of revenue | 23.43%90.98M | 25.32%23.89M | 27.33%23.34M | 20.09%22.56M | 21.11%21.2M | 2.67%73.71M | 23.73%19.06M | 5.00%18.33M | -4.69%18.78M | -8.93%17.5M |
Gross profit | 3.89%117.7M | -0.03%30.28M | 1.53%29.82M | 6.32%28.59M | 8.37%29M | -4.44%113.28M | 14.03%30.29M | -2.83%29.37M | -13.22%26.89M | -13.03%26.76M |
Operating expense | 17.20%119.2M | 15.67%30.2M | 20.36%31.3M | 19.12%29.69M | 13.55%28.02M | -48.80%101.7M | 0.50%26.11M | -72.98%26M | -43.13%24.92M | -24.29%24.67M |
Selling and administrative expenses | -0.09%32.84M | 6.96%8.96M | -5.46%7.75M | -3.97%7.58M | 1.74%8.55M | -17.16%32.87M | -19.67%8.38M | -24.16%8.2M | -11.95%7.89M | -11.29%8.4M |
-General and administrative expense | -0.09%32.84M | 6.96%8.96M | -5.46%7.75M | -3.97%7.58M | 1.74%8.55M | -17.16%32.87M | -19.67%8.38M | -24.16%8.2M | -11.95%7.89M | -11.29%8.4M |
Depreciation amortization depletion | 25.46%86.36M | 19.79%21.24M | 32.25%23.55M | 29.82%22.11M | 19.65%19.47M | -56.70%68.83M | 14.03%17.73M | -79.16%17.8M | -51.15%17.03M | -29.62%16.27M |
-Depreciation and amortization | 25.46%86.36M | 19.79%21.24M | 32.25%23.55M | 29.82%22.11M | 19.65%19.47M | -56.70%68.83M | 14.03%17.73M | -79.16%17.8M | -51.15%17.03M | -29.62%16.27M |
Operating profit | -112.96%-1.5M | -98.02%83K | -143.73%-1.47M | -155.63%-1.1M | -52.78%987K | 114.46%11.58M | 616.10%4.18M | 105.11%3.37M | 115.35%1.97M | 215.02%2.09M |
Net non-operating interest income expense | -115.83%-60.41M | -153.06%-18.67M | -190.18%-16.73M | -99.01%-14.29M | -39.85%-10.72M | 59.90%-27.99M | -23.74%-7.38M | 34.51%-5.77M | 82.48%-7.18M | 45.42%-7.67M |
Non-operating interest income | -0.81%9.65M | -19.90%2.17M | -7.52%2.3M | 2.30%2.54M | 28.67%2.65M | 140.15%9.73M | 34.38%2.71M | 171.69%2.49M | 338.58%2.48M | 270.81%2.06M |
Non-operating interest expense | 85.74%70.06M | 106.60%20.84M | 130.62%19.03M | 74.19%16.82M | 37.48%13.37M | -48.92%37.72M | 26.43%10.09M | -15.09%8.25M | -76.76%9.66M | -33.39%9.73M |
Other net income (expense) | 70.61%-45.17M | 105.66%8.61M | -164.97%-5.67M | -1,070.82%-47.91M | 95.63%-191K | -159.26%-153.67M | 26.53%-152.1M | -102.34%-2.14M | -98.60%4.94M | -119.95%-4.37M |
Gain on sale of security | 35.69%12.35M | 1,468.49%59.29M | -1,444.14%-1.71M | -833.66%-46.62M | 258.18%1.67M | -95.94%9.1M | 126.82%3.78M | -100.13%-111K | -95.50%6.36M | -105.63%-1.06M |
Earnings from equity interest | 66.52%-51.94M | ---- | ---- | ---- | -86.82%41K | 2.41%-155.11M | ---- | ---- | ---- | -92.53%311K |
Special income (charges) | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Other non- operating income (expenses) | 27.11%-5.58M | 263.28%1.25M | -95.02%-3.96M | 9.44%-1.29M | 47.49%-1.9M | 40.15%-7.66M | 91.02%-768K | -52.75%-2.03M | 29.77%-1.42M | -255.49%-3.63M |
Income before tax | 37.04%-107.07M | 93.58%-9.98M | -426.43%-23.88M | -23,083.52%-63.29M | 0.23%-9.93M | -255.43%-170.07M | 26.89%-155.3M | -127.31%-4.54M | -100.09%-273K | -264.28%-9.95M |
Income tax | 13.18%-11.07M | -21.31%-2.34M | 38.58%-3.81M | -424.70%-2.19M | 34.94%-2.73M | -173.86%-12.75M | 72.73%-1.93M | 64.64%-6.21M | -100.91%-417K | -3.45%-4.2M |
Net income | 38.98%-96M | 95.02%-7.64M | -1,298.63%-20.07M | -42,532.64%-61.1M | -25.08%-7.2M | -270.71%-157.32M | 25.31%-153.37M | -95.10%1.67M | -99.94%144K | -156.89%-5.75M |
Net income continuous Operations | 38.98%-96M | 95.02%-7.64M | -1,298.63%-20.07M | -42,532.64%-61.1M | -25.08%-7.2M | -270.71%-157.32M | 25.31%-153.37M | -95.10%1.67M | -99.94%144K | -156.89%-5.75M |
Minority interest income | -27.14%6.47M | 216.92%2.18M | -52.44%1.87M | -115.40%-577K | -2.42%2.99M | -45.98%8.88M | 56.02%-1.87M | -16.32%3.93M | -73.38%3.75M | 61.01%3.06M |
Net income attributable to the parent company | 38.35%-102.47M | 93.52%-9.82M | -870.62%-21.94M | -1,580.34%-60.53M | -15.53%-10.19M | -319.47%-166.2M | 24.66%-151.5M | -107.67%-2.26M | -101.51%-3.6M | -207.41%-8.82M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | 0 | 0 | ||||||||
Net income attributable to common stockholders | 38.35%-102.47M | 93.52%-9.82M | -870.62%-21.94M | -1,580.34%-60.53M | -15.53%-10.19M | -319.47%-166.2M | 24.66%-151.5M | -107.67%-2.26M | -101.53%-3.6M | -208.92%-8.82M |
Basic earnings per share | 35.34%-0.75 | 92.52%-0.08 | -700.00%-0.16 | -2,050.00%-0.43 | -16.67%-0.07 | -332.00%-1.16 | 20.15%-1.07 | -110.53%-0.02 | -101.27%-0.02 | -220.00%-0.06 |
Diluted earnings per share | 35.34%-0.75 | 92.52%-0.08 | -700.00%-0.16 | -2,050.00%-0.43 | -16.67%-0.07 | -336.73%-1.16 | 20.15%-1.07 | -110.53%-0.02 | -101.27%-0.02 | -220.00%-0.06 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |